SYNCOMF

Consolidated Revenue for the year ended March 31, 2026, was ₹48,917.15 Lacs vs ₹46,501.26 Lacs (▲5.20% YoY), EBITDA was ₹7,746.69 Lacs vs ₹5,413.75 Lacs (▲43.10% YoY), and PAT was ₹7,643.80 Lacs vs ₹4,943.46 Lacs (▲54.62% YoY). EBITDA Margin expanded to 15.84% vs 11.64% (▲420bps). The auditor has issued an unmodified opinion on the financial results.

Syncom Formulations (India) Limited disclosed the successful acquisition of a commercial property, the entire 7th Floor of Trade Star, Andheri-Kurla Road, Mumbai, from HDFC Bank Ltd. The company paid a total consideration of Rs. 57,26,00,000/- (Rupees 57.26 Crores) for the acquisition.

Syncom Formulations (India) Limited submitted the Regulation 74(5) SEBI (Depository and Participants) Regulations, 2018 compliance certificate for the quarter ended March 31, 2026. The RTA confirmed timely processing of dematerialization requests and cancellation of physical certificates.

Syncom Formulations (India) Limited submitted its yearly disclosure under SEBI (SAST) Regulations 31(4) for the financial year ended March 31, 2026. The promoters and Persons Acting in Concert declared no new encumbrances in the company's securities beyond those already disclosed.

Syncom Formulations (India) Limited announced the closure of its trading window from April 1, 2026, until 48 hours after the declaration of Audited Standalone & Consolidated Financial Results for the Quarter and Year ended March 31, 2026, to prevent insider trading.

Consolidated Revenue ₹11,514.06 Lakhs vs ₹12,753.32 Lakhs (▼9.72% YoY), EBITDA ₹2,671.14 Lakhs vs ₹1,876.79 Lakhs (▲42.33% YoY), PAT ₹1,890.81 Lakhs vs ₹1,300.20 Lakhs (▲45.42% YoY). EBITDA Margin 23.20% vs 14.71% (▲849bps). The company has received an intimation for rejection of appeal and demand of ₹1.42 Cr towards ineligible Input Tax Credit and penalty, which it plans to contest.